Table 5 Randomized trials and metaanalyses evaluating the role systemic adjuvant chemotherapy in patients with completely resected colorectal liver metastases
Authors (year) | Type of study | No | Randomized postoperative chemotherapy | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|
Langer B (2002) [56] | Phase III | 129 | 5FU/LV | No difference | No difference |
Portier (2006) [57] | Phase III | 173 | 5FU/LV | 24.4 vs. 16.6 (p = 0.028) | 62.1 vs. 46.4 (p = 0.13) |
Mirty (2006) [58] | Pooled analysis | 278 | 5FU/LV | 27.9 vs. 18..8 (p = 0.059) | 61.1 vs. 46.9 (p = 0.125) |
Ychou (2009) [59] | Phase III | 306 | FOLFIRI vs. 5FU/LV | 24.7 vs. 21.6 (p = 0.44) | No difference |
Voest (2011) [60] | Phase III | 79 | Bevacizumab + XELOX vs. XELOX | 2 years PFS = 70% vs. 52% (p = 0.074) | - |